Literature DB >> 24042540

Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study.

Françoise Bonichon1, Jean Palussière, Yann Godbert, Marina Pulido, Edouard Descat, Anne Devillers, Catherine Meunier, Sophie Leboulleux, Thierry de Baère, Claire Galy-Lacour, Laurent Lagoarde-Segot, Anne-Laure Cazeau.   

Abstract

PURPOSE: To assess diagnostic accuracy of (18)F-FDG PET/CT at 3 months for the detection of local recurrence after radiofrequency ablation (RFA) of lung metastases.
METHODS: The PET/CT scan at 3 months was compared with a baseline PET/CT scan from a maximum of 2 months before RFA, with the reference standard as recurrence diagnosed by CT during a 12-month follow-up. Local recurrence was diagnosed on the PET/CT scan if lesional uptake was greater than the mediastinal background. Maximum standardized uptake values (SUVmax) were recorded. ROC curve analysis for SUVmax was performed. Overall survival (OS) and time to local relapse were computed from the date of RFA using the Kaplan-Meier method (www.clinicaltrials.gov: NCT 00382252).
RESULTS: Between 2005 and 2009, 89 patients (mean age 65 years) underwent RFA for 115 lung metastases (mean size 16.2 ± 6.9 mm). The median SUVmax before RFA was 5.8 ± 4. PET/CT at 3 months and the reference standard were available in 77 patients and 100 lesions. Accuracy was 66.00% (95% CI 55.85-75.18%), sensitivity 90.91% (95 % CI 58.72-99.77 %), specificity 62.92% (95% CI 52.03-72.93%), PPV 23.26% (95% CI 11.76-38.63%), and NPV 98.25% (95% CI 90.61-99.96%). One-year OS was 94.2% (95% CI 86.6-97.5%) and the probability of being free of local recurrence 1 year after RFA was 84.6% (95% CI 75.0-90.8%).
CONCLUSION: The specificity of PET/CT at 3 months is low because of persistent inflammation, especially when the lesion is close to the pleura. This technique is useful for its negative predictive value, but positive findings need to be confirmed by histology before new treatment is planned.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24042540     DOI: 10.1007/s00259-013-2521-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  37 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Long-term outcome of image-guided percutaneous radiofrequency ablation of lung metastases: an open-labeled prospective trial of 148 patients.

Authors:  T C Chua; A Sarkar; A Saxena; D Glenn; J Zhao; D L Morris
Journal:  Ann Oncol       Date:  2010-03-24       Impact factor: 32.976

Review 3.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

4.  Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan.

Authors:  Koichiro Yamakado; Soichiro Hase; Toshiyuki Matsuoka; Noboru Tanigawa; Atsuhiro Nakatsuka; Haruyuki Takaki; Motoshi Takao; Yoshihiro Inoue; Susumu Kanazawa; Yuichi Inoue; Satoshi Sawada; Masato Kusunoki; Kan Takeda
Journal:  J Vasc Interv Radiol       Date:  2007-03       Impact factor: 3.464

5.  Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors.

Authors:  Amita Sharma; Michael Lanuti; Wei He; Edwin L Palmer; Jo-Anne O Shepard; Subba R Digumarthy
Journal:  J Comput Assist Tomogr       Date:  2013 Jan-Feb       Impact factor: 1.826

6.  Detection of local tumor progression by (18)F-FDG PET/CT following lung radiofrequency ablation: PET versus CT.

Authors:  Naohisa Suzawa; Koichiro Yamakado; Motoshi Takao; Osamu Taguchi; Tomomi Yamada; Kan Takeda
Journal:  Clin Nucl Med       Date:  2013-04       Impact factor: 7.794

7.  Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma.

Authors:  Tristan D Yan; Julie King; Adrian Sjarif; Derek Glenn; Karin Steinke; Ahmed Al-Kindy; David L Morris
Journal:  Ann Surg Oncol       Date:  2007-02-07       Impact factor: 5.344

8.  Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients.

Authors:  Caroline J Simon; Damian E Dupuy; Thomas A DiPetrillo; Howard P Safran; C Alexander Grieco; Thomas Ng; William W Mayo-Smith
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

9.  Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor.

Authors:  Fumiyo Higaki; Yoshihiro Okumura; Shuhei Sato; Takao Hiraki; Hideo Gobara; Hidefumi Mimura; Shiro Akaki; Toshihide Tsuda; Susumu Kanazawa
Journal:  Ann Nucl Med       Date:  2008-05-23       Impact factor: 2.668

Review 10.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W De Vet
Journal:  AJR Am J Roentgenol       Date:  2003-07       Impact factor: 3.959

View more
  6 in total

Review 1.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

2.  Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network.

Authors:  Françoise Bonichon; Thierry de Baere; Amandine Berdelou; Sophie Leboulleux; Anne-Laure Giraudet; Marie Cuinet; Delphine Drui; Renan Liberge; Antony Kelly; Florence Tenenbaum; Paul Legmann; Christine Do Cao; Laurence Leenhardt; Michel Toubeau; Yann Godbert; Jean Palussière
Journal:  Endocrine       Date:  2021-03-26       Impact factor: 3.633

3.  Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702).

Authors:  Hideo Gobara; Yasuaki Arai; Takeshi Kobayashi; Koichiro Yamakado; Yoshitaka Inaba; Yoshihisa Kodama; Takuji Yamagami; Miyuki Sone; Hirokazu Watanabe; Yoshihiro Okumura; Takayoshi Shinya; Hiroaki Kurihara; Susumu Kanazawa
Journal:  Jpn J Radiol       Date:  2016-06-03       Impact factor: 2.374

Review 4.  Radiofrequency ablation for lung squamous cell carcinoma in a single-lung patient: A case report and literature review.

Authors:  Guo-Qiang Song; Guan-Gnan Li; Fei Chen; Dun-Shun Chen; Hui-Juan Qian; Xiao-E Deng; Huo-Quan Lu; Bin Lin
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

5.  Percutaneous radiofrequency ablation in the treatment of pulmonary malignancies: efficacy, safety and predictive factors.

Authors:  Tina Streitparth; Denis Schumacher; Robert Damm; Bjoern Friebe; Konrad Mohnike; Ortrud Kosiek; Maciej Pech; Jens Ricke; Florian Streitparth
Journal:  Oncotarget       Date:  2018-01-18

6.  Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial.

Authors:  J Palussière; F Chomy; M Savina; F Deschamps; J Y Gaubert; A Renault; O Bonnefoy; F Laurent; C Meunier; C Bellera; S Mathoulin-Pelissier; T de Baere
Journal:  J Cardiothorac Surg       Date:  2018-08-24       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.